BioNTech Acquires Biotheus to Strengthen Oncology Pipeline with Bispecific Antibody Asset BNT327/PM8002

BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Biotheus (“Biotheus”) announced the signing of a definitive agreement for...

November 14, 2024 | Thursday | News
TrakCel's OCELLOS Platform Chosen to Support Five Key Cell Therapy Products in 2024, Streamlining CGT Supply Chain Management

TrakCel, a provider of integrated cell and gene therapy (CGT) orchestration solutions for the precise management, control and tracking of CGTs has announce...

November 13, 2024 | Wednesday | News
Adragos Pharma Expands Production with €13 Million Investment in New Ampoule Filling Line, Boosting Capacity by 30%

Adragos Pharma, a leading Contract Development & Manufacturing Organisation (CDMO), has significantly enhanced its production capabilities with the com...

November 13, 2024 | Wednesday | News
GHIT Fund Commits JPY 578 Million to Pioneering Projects Targeting Malaria and Neglected Tropical Diseases

The Global Health Innovative Technology (GHIT) Fund announced a total investment of approximately JPY 578 million (USD 4.0 million1) in four...

November 07, 2024 | Thursday | News
Syndax Pharmaceuticals Secures $350 Million Synthetic Royalty Funding Agreement with Royalty Pharma for Niktimvo™

Syndax Pharmaceuticals (Nasdaq: SNDX) and Royalty Pharma plc (Nasdaq: RPRX) announced that Syndax has entered into a $350 million synth...

November 05, 2024 | Tuesday | News
Yvonne Greenstreet of Alnylam Pharmaceuticals Reports 34% Revenue Growth in Q3, Driven by TTR Success and Strong Pipeline Progress

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, reported its consolidated financial results for the third quarter...

November 01, 2024 | Friday | News
AbbVie and EvolveImmune Forge Partnership to Develop Next-Gen Cancer Therapies

AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics, an immuno-oncology company developing next-generation biotherapeutics to overcome the therapeutic c...

November 01, 2024 | Friday | News
Biogen and Neomorph Forge Collaboration to Develop Molecular Glue Degraders for Neurological and Immunological Diseases

 Biogen Inc. (Nasdaq: BIIB) and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for priority ta...

October 30, 2024 | Wednesday | News
MilliporeSigma Rolls Out €70 Million Expansion to Transform St. Louis into a Hub for Advanced ADC Manufacturing and Biopharma Innovation

Merck, a leading science and technology company, announced a € 70 million expansion of its ADC manufacturing capabilities and capacity at its Bioconju...

October 30, 2024 | Wednesday | News
Grifols Partners with BARDA to Develop Eye Drops for Sulfur Mustard Ocular Injury

Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, announced it has established a...

October 23, 2024 | Wednesday | News
Samsung Biologics Secures Landmark $1.24 Billion Contract with Asia-Based Pharma

INCHEON, South Korea, Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), announced a contra...

October 22, 2024 | Tuesday | News
Sanofi and CD&R Announce Exclusive Negotiations for 50% Stake in Opella, Poised to Create Global Consumer Healthcare Leader

 Sanofi and CD&R announce a plan to join forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare champion. S...

October 22, 2024 | Tuesday | News
Foresee Pharmaceuticals Completes Phase 1 Trial of Linvemastat, a Promising Oral MMP-12 Inhibitor for Respiratory and IBD Conditions

Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") announced the successful completion of its Phase 1 single and multiple ascending dose (SAD/MAD) clinical ...

October 21, 2024 | Monday | News
Amicus Therapeutics and Teva Pharmaceuticals Reach License Agreement on GALAFOLD®

Amicus Therapeutics (Nasdaq: FOLD) announced that it has entered into a License Agreement (Agreement) with Teva Pharmaceuticals USA, Inc. and Teva Pharmace...

October 18, 2024 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close